Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2022
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+43.8%
|
-
|
|
Jan 21
2022
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+41.85%
|
-
|
|
Jan 21
2022
|
Federico Grossi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+19.94%
|
-
|
|
Jan 21
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+36.3%
|
-
|
|
Jan 21
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+2.83%
|
-
|
|
Jan 21
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,787
+22.69%
|
-
|
|
Jan 21
2022
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
106,244
+7.34%
|
-
|
|
Jan 21
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+31.85%
|
-
|
|
Jan 21
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,021
+9.24%
|
$78,546
$26.73 P/Share
|
|
Jan 14
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.48%
|
$15,000
$40.56 P/Share
|
|
Jan 14
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,400
+4.13%
|
$13,600
$4.31 P/Share
|
|
Jan 14
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.19%
|
$50,000
$40.56 P/Share
|
|
Jan 14
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.18%
|
$2,500
$2.67 P/Share
|
|
Jan 12
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,161
+3.33%
|
$20,644
$4.04 P/Share
|
|
Jan 03
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.53%
|
$17,625
$47.31 P/Share
|
|
Jan 01
2022
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+5.61%
|
-
|
|
Jan 01
2022
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+50.0%
|
-
|
|
Jan 01
2022
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+0.62%
|
-
|
|
Jan 01
2022
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+31.43%
|
-
|
|
Jan 01
2022
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+50.0%
|
-
|
|
Dec 27
2021
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
1,200
-1.1%
|
$57,600
$48.5 P/Share
|
|
Dec 22
2021
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-1.19%
|
$4,183
$47.82 P/Share
|
|
Dec 22
2021
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
10,571
-3.16%
|
$507,408
$48.05 P/Share
|
|
Dec 22
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,112
+4.41%
|
$281,568
$14.4 P/Share
|
|
Dec 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
3,000
-0.45%
|
$126,000
$42.88 P/Share
|
|
Dec 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.44%
|
$6,000
$2.67 P/Share
|
|
Dec 15
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.53%
|
$15,750
$42.88 P/Share
|
|
Dec 08
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+8.96%
|
$21,000
$3.76 P/Share
|
|
Dec 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.58%
|
$15,750
$42.4 P/Share
|
|
Nov 18
2021
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+1.91%
|
$10,000,000
$40.0 P/Share
|
|
Nov 15
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
625
-0.96%
|
$26,875
$43.5 P/Share
|
|
Nov 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
3,000
-0.45%
|
$129,000
$43.5 P/Share
|
|
Nov 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.44%
|
$6,000
$2.67 P/Share
|
|
Nov 04
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
3,000
-0.45%
|
$105,000
$35.0 P/Share
|
|
Nov 04
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.44%
|
$6,000
$2.67 P/Share
|
|
Nov 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
625
-0.96%
|
$18,750
$30.7 P/Share
|
|
Oct 26
2021
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
882
+7.17%
|
-
|
|
Oct 20
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
882
+7.84%
|
-
|
|
Oct 20
2021
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
882
+9.42%
|
-
|
|
Oct 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
750
-1.13%
|
$25,500
$34.57 P/Share
|
|
Oct 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
750
-1.12%
|
$24,750
$33.26 P/Share
|
|
Sep 28
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+5.64%
|
$12,000
$3.76 P/Share
|
|
Sep 10
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
954
+0.95%
|
$3,816
$4.31 P/Share
|
|
Sep 10
2021
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,894
+9.34%
|
$96,516
$14.0 P/Share
|
|
Aug 30
2021
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+50.0%
|
-
|
|
Aug 16
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$140,000
$56.95 P/Share
|
|
Aug 16
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Aug 02
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$63,000
$63.99 P/Share
|
|
Aug 02
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Aug 02
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
250
-0.4%
|
$15,750
$63.99 P/Share
|